Future trends in the treatment of non-alcoholic steatohepatitis
The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
Graphical abstract Figure. No caption available. &NA; With an estimated prevalence of ≈25% in Western and Asian countries, non alcoholic fatty liver disease (NAFLD), caused by chronic excessive caloric intake, is the emerging as the most prevalent liver disorder worldwide. NAFLD exists in two clinical entities, non‐alcoholic fatty liver disease (NAFL), a relative benign disease that carry on minimal risk of liver‐related morbidity but significant risk of cardiovascular complications, and non‐alcoholic steatohepatitis (NASH), a progressive liver disorder with a significant risk for development of liver‐related morbidities and mortality. While, liver injury in NASH is contributed by lipid overload in hepatocytes, lipotoxicity, the main determinant of disease progression is an inflammation‐driven fibrotic response. Here, we review the landscape of emerging pharmacological interventions in the treatment of NAFL and NASH. A consensus exists that, while treating the liver component of NASH requires development of novel pharmacological approaches, the future therapy of NASH needs to be tailored to the single patient and most likely will be a combination of agents acting on specific pathogenic mechanisms at different disease stage.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention
Younossi, Z., Anstee, Q. M., Marietti, M., Hardy, T., Henry, L., Eslam, M., George, J., & Bugianesi, E. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.109 · Cited by 5,249 · cited 1×
“Paralleling the global pandemia of diabetes and obesity, the prevalence of NAFLD has increased stably in the last two decades worldwide, reaching the highest prevalence in South America (31%) and the Middle East (32%), followed by Asia (27%), the USA (24%) and Europe (23%) [1,2].”
BackgroundEASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
(2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.11.004 · Cited by 4,836
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896 · cited 2×
“GLP-1 is a gastrointestinal incretin released from the “L” type endocrine cells most abundant in the distal ileum [17,18,30].”
BackgroundNeuschwander-Tetri, B. A., Loomba, R., Sanyal, A. J., Lavine, J. E., Van Natta, M. L., Abdelmalek, M. F., Chalasani, N., Dasarathy, S., Diehl, A. M., Hameed, B., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61933-4 · Cited by 2,237
Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis
Inagaki, T., Choi, M., Moschetta, A., Peng, L., Cummins, C. L., McDonald, J. G., Luo, G., Jones, S. A., Goodwin, B., Richardson, J. A., et al. (2005) · Cell Metabolism · doi:10.1016/j.cmet.2005.09.001 · Cited by 1,865
Ratziu, V., Harrison, S. A., Francque, S., Bedossa, P., Lehert, P., Serfaty, L., Romero-Gomez, M., Boursier, J., Abdelmalek, M., Caldwell, S., et al. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.01.038 · Cited by 1,035
Lipotoxicity and the gut-liver axis in NASH pathogenesis
Marra, F., & Svegliati-Baroni, G. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2017.11.014 · Cited by 847
Friedman, S. L., Ratziu, V., Harrison, S. A., Abdelmalek, M. F., Aithal, G. P., Caballeria, J., Francque, S., Farrell, G., Kowdley, K. V., Craxi, A., et al. (2018) · Hepatology · doi:10.1002/hep.29477 · Cited by 671
Circulating FGF21 Is Liver Derived and Enhances Glucose Uptake During Refeeding and Overfeeding
Markan, K. R., Naber, M. C., Ameka, M. K., Anderegg, M. D., Mangelsdorf, D. J., Kliewer, S. A., Mohammadi, M., & Potthoff, M. J. (2014) · Diabetes · doi:10.2337/db14-0595 · Cited by 590
Bile Acid-Activated Receptors, Intestinal Microbiota, and the Treatment of Metabolic Disorders
Fiorucci, S., & Distrutti, E. (2015) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2015.09.001 · Cited by 539
Self-citationDeterminants of Fibrosis Progression and Regression in NASH
Schuppan, D., Surabattula, R., & Wang, X. Y. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2017.11.012 · Cited by 479
Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis
Armstrong, M. J., Hull, D., Guo, K., Barton, D., Hazlehurst, J. M., Gathercole, L. L., Nasiri, M., Yu, J., Gough, S. C., Newsome, P. N., et al. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.08.038 · Cited by 456 · cited 2×
“GLP-1 is a gastrointestinal incretin released from the “L” type endocrine cells most abundant in the distal ileum [17,18,30].”
BackgroundZhou, D., Pan, Q., Shen, F., Cao, H.-X., Ding, W.-J., Chen, Y.-W., & Fan, J.-G. (2017) · Scientific Reports · doi:10.1038/s41598-017-01751-y · Cited by 421 · cited 1×
“Probiotic and fecal microbiota transplantation have shown beneficial effects in rodent models of NASH [96,97], suggesting that modulation of gut microbiota through probiotics and/or symbiontics (that target protozoa) could provide a beneficial effect in NASH patients.”
BackgroundKim, C.-W., Addy, C., Kusunoki, J., Anderson, N. N., Deja, S., Fu, X., Burgess, S. C., Li, C., Ruddy, M., Chakravarthy, M., et al. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2017.07.009 · Cited by 419
Staels, B., Rubenstrunk, A., Noel, B., Rigou, G., Delataille, P., Millatt, L. J., Baron, M., Lucas, A., Tailleux, A., Hum, D. W., et al. (2013) · Hepatology · doi:10.1002/hep.26461 · Cited by 414
Biagioli, M., Carino, A., Cipriani, S., Francisci, D., Marchianò, S., Scarpelli, P., Sorcini, D., Zampella, A., & Fiorucci, S. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.1700183 · Cited by 327
Self-citationLefebvre, E., Moyle, G., Reshef, R., Richman, L. P., Thompson, M., Hong, F., Chou, H.-L., Hashiguchi, T., Plato, C., Poulin, D., et al. (2016) · PLOS ONE · doi:10.1371/journal.pone.0158156 · Cited by 323 · cited 1×
“3 and 4) is an antifibrotic agents that was shown effective in attenuating liver and kidney fibrosis in rodents [72].”
BackgroundIbrahim, S. H., Hirsova, P., & Gores, G. J. (2018) · Gut · doi:10.1136/gutjnl-2017-315691 · Cited by 278 · cited 1×
“The injured hepatocytes release a number of inflammatory mediators including: 1) sonic hedgehog, which activates the hedgehog signaling, a pathway that is essential for liver repair and regeneration but if persistently activated might induce fibrosis [21], 2) pro-apoptotic factors such as caspase 9; and 3) cell damage…”
BackgroundLiao, H.-W., Saver, J. L., Wu, Y.-L., Chen, T.-H., Lee, M., & Ovbiagele, B. (2017) · BMJ Open · doi:10.1136/bmjopen-2016-013927 · Cited by 198
Intestinal Microbiota and Nonalcoholic Steatohepatitis
Brandl, K., & Schnabl, B. (2017) · Current Opinion in Gastroenterology · doi:10.1097/mog.0000000000000349 · Cited by 169 · cited 1×
“Intestinal dysbiosis is considered a causative mechanisms of NASH, at least in animal models [26].”
BackgroundGarcía‐Lezana, T., Raurell, I., Bravo, M., Torres‐Arauz, M., Salcedo, M. T., Santiago, A., Schoenenberger, A., Manichanh, C., Genescà, J., Martell, M., et al. (2018) · Hepatology · doi:10.1002/hep.29646 · Cited by 136
Gege, C., Kinzel, O., Steeneck, C., Schulz, A., & Kremoser, C. (2014) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026614666141112094430 · Cited by 69
Investigational glucagon-like peptide-1 agonists for the treatment of obesity
Tomlinson, B., Hu, M., Zhang, Y., Chan, P., & Liu, Z.-M. (2016) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2016.1221925 · Cited by 25
Cited by
Bile acids and their receptors in metabolic disorders
Fiorucci, S., Distrutti, E., Carino, A., Zampella, A., & Biagioli, M. (2021) · Progress in Lipid Research · doi:10.1016/j.plipres.2021.101094 · Cited by 258
Self-citationNon‐alcoholic fatty liver disease: a review of epidemiology, risk factors, diagnosis and management
Huang, T. (., Behary, J., & Zekry, A. (2020) · Internal Medicine Journal · doi:10.1111/imj.14709 · Cited by 227
Calle, R. A., Amin, N. B., Carvajal-Gonzalez, S., Ross, T. T., Bergman, A., Aggarwal, S., Crowley, C., Rinaldi, A., Mancuso, J., Aggarwal, N., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01489-1 · Cited by 219
Acetyl-CoA Carboxylase Inhibition Improves Multiple Dimensions of NASH Pathogenesis in Model Systems
Ross, T. T., Crowley, C., Kelly, K. L., Rinaldi, A., Beebe, D. A., Lech, M. P., Martinez, R. V., Carvajal-Gonzalez, S., Boucher, M., Hirenallur-Shanthappa, D., et al. (2020) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2020.06.001 · Cited by 94
“Pharmacologic agents, or combinations of pharmacologic agents, that address multiple aspects of this pathogenic cascade may be particularly valuable for therapeutic intervention in NASH given this complex and multifactorial disease pathogenesis.(2) Hepatic steatosis is a consequence of an imbalance in”
Background
Metadata
- Authors
- Fiorucci, S., Biagioli, M., & Distrutti, E.
- Venue
- Pharmacological Research
- Publisher
- Elsevier BV
- Published
- 2018-08
- Volume
- 134
- Pages
- 289-298
- ISSN
- 1043-6618 (ISSN-L)
- OpenAlex
- W2883449168
- Cited by
- 53
- References
- 23
- FWCI
- 6.99
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.